The Evolving Therapeutics of Endothelial Disease
Eye Banking and Corneal Transplantation · 2023
DOI: 10.1097/ebct.0000000000000015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eye Banking and Corneal Transplantation, 2023. Verfasst von Marcela Huertas-Bello und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Endothelial dysfunction is one of the leading indications for corneal transplantation. Globally, there is a shortage of donor corneas, which is partly because of the lack of eye banking resources in emerging countries. Given this global shortage, there is naturally heightened interest surrounding pharmacological agents, genetic therapy, and endothelial cell–based therapeutic modalities. Endothelial cells have limited mitotic capacity in vivo, and thus, studies have been conducted for their ex vivo expansion using mitogens. Similarly, pluripotent stem cells have been used to differentiate into human corneal endothelial cells with varying degrees of success. Different strategies have also been developed for injecting and delivering these cells into the human eye. This review aims to compile the information published on the latest advances in endothelial disease therapy.
Zitieren
APA
Huertas-Bello, M., Sabater, A. L., & Koo, E. H. (2023). The Evolving Therapeutics of Endothelial Disease. Eye Banking and Corneal Transplantation. https://doi.org/10.1097/ebct.0000000000000015
Vancouver
Huertas-Bello M, Sabater AL, Koo EH. The Evolving Therapeutics of Endothelial Disease. Eye Banking and Corneal Transplantation. 2023. doi:10.1097/ebct.0000000000000015
BibTeX
@article{HuertasBello2023,
author = {Huertas-Bello, Marcela and Sabater, Alfonso L. and Koo, Ellen H.},
title = {The Evolving Therapeutics of Endothelial Disease},
journal = {Eye Banking and Corneal Transplantation},
year = {2023},
doi = {10.1097/ebct.0000000000000015}
}
EUVIMED